Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 /PRNewswire-USNewswire/ ... unforgiving environments. Human exploration of space requires astronauts to ... mission safety and success, and prevent potential errors and ... success, little is known about how cognition is affected ... primarily affected. Now, Penn Medicine researchers are ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology ... science community to the UMBC campus for a discussion ... Protein Society, will take place from 9 a.m. to ... Through discussion, presentations and workshops, the free symposium will ... role in the industry and the future of protein ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation ... of sites that provide clinical research services to pharmaceutical companies ... through its partnerships with large physician practices and integrated health ... in the Southeastern United States and spans over 60 physician ... will be held by: Dr. Robert Holmes, MD, of ...
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... 15, 2011 This evening, Novo Nordisk awarded sponsorships ... support programs that educate people living with type 2 ... reduce the risk of long-term diabetes related complications. The ... program – a new initiative that aims to promote ...
... 15, 2011 Roka Bioscience announced today that the ... certification of the Listeria Detection Assay. This evaluation is ... (AOAC-RI) certification of methods used in the food safety ... laboratory and monitored by AOAC. The internal portion of ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... leading Chinese pharmaceutical company, today announced that Shanghai ... and Hengrui have entered into a strategic partnership ...
Cached Biology Technology:Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 2Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 3Roka Bioscience Initiates External Trial for AOAC Certification 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 3
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
Breaking Biology News(10 mins):PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... therapy (ECT) is the most effective acute treatment for ... ECT, there remains a significant risk of adverse cognitive ... that the regions that need to be stimulated to ... from the regions that result in memory problems (the ...
... study led by researchers from Harvard School of Public ... the UK has, for the first time, used genome ... population following the introduction of a vaccine. The study ... the introduction of the ,Prevnar, conjugate polysaccharide vaccine, which ...
... University of Manchester scientists, writing in the journal Nature ... can both have an unexpected cooling effect on the world,s ... water droplets, condensed on to tiny particles suspended in the ... into cloud droplets. It has been known for some decades ...
Cached Biology News:Researchers reveal new more precise method of performing electroconvulsive therapy 2Genome sequencing provides unprecedented insight into causes of pneumococcal disease 2Organic vapors affect clouds leading to previously unidentified climate cooling 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
with GlutaMAXIL-glutamine...
alpha N-catenin (C-19)...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Biology Products: